Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724519 | 0.95 | NPC1 (0.36) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4723526 | 0.92 | NPC1 (0.35) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4723421 | 0.86 | NPC1 (0.35) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4721786 | 0.83 | CYP3A4 (0.35) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4719922 | 0.79 | MALT1 (0.35) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4723288 | 0.77 | NPC1 (0.38) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4724574 | 0.76 | NPC1 (0.37) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4765499 | 0.75 | ALDH1A1 (0.40) | NPC1RAB9ACYP1A2 | |
| SCHEMBL4723782 | 0.74 | ALDH1A1 (0.37) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2957703 | 0.72 | CYP1A2 (0.37) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | NPC1 3867/4885RAB9A 2943/4885CYP1A2 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.